Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma
Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma
The purpose of the phase I part is to determine the tolerability, the initial safety profile
 and maximum tolerated dose of oxaliplatin in combination with gemcitabine for indolent
 lymphoma. In the phase II part the investigators want to estimate the activity of gemcitabine
 and oxaliplatin in combination with rituximab for patients with relapsed/refractory indolent
 lymphoma.
Inclusion Criteria:

 -  Need for therapy in patients with relapsed/refractory patients

 -  Histological proven diagnosis of an indolent B-cell lymphoma according to the World
 Health Organization (WHO) classification belonging to one of the following entities:

 -  follicular lymphoma

 -  mantle cell lymphoma

 -  lymphoplasmacytic lymphoma

 -  nodal or splenic marginal zone lymphoma

 -  measurable disease

 -  lymphoma specific therapy in the last four weeks

 -  WHO performance grade 0, 1 or 2

 Exclusion Criteria

 -  Patients suitable for high dose therapy

 -  Transformation in high grade lymphoma

 -  Leukocytes < 1,5/nl or platelets < 100/nl (except due to lymphoma)